Drug Delivery Systems of Natural Products in Oncology
Abstract
:1. Introduction: Limitations of Anticancer Therapies
2. Nanomedicine and Drug Delivery
2.1. Organic Nanoparticles
2.1.1. Lipid-based NPs
2.1.2. Exosomes
2.1.3. Carbon-based Nanoparticles (Carbon Nanotubes and Graphene Nanoplatelets)
2.1.4. Polymeric Nanoparticles
2.2. Metallic and Magnetic Nanoparticles
2.3. Active and Passive Target
3. Natural Products and Drug Delivery in Oncology
4. FDA Approved Nanodevices
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- NIH National Cancer Institute. Available online: https://www.cancer.gov/about-cancer/understanding/statistics (accessed on 30 July 2020).
- European Commission. Available online: https://ec.europa.eu/jrc/en/publication/cancer-incidence-and-mortality-patterns-europe (accessed on 30 July 2020).
- NIH National Cancer Institute. Available online: https://www.cancer.gov/about-cancer/treatment (accessed on 30 July 2020).
- Falzone, L.; Salomone, S.; Libra, M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front. Pharmacol. 2018, 9, 1300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peters, G.J. Cancer drug resistance: A new perspective. Cancer Drug Resist. 2018, 1, 1–5. [Google Scholar] [CrossRef] [Green Version]
- Alfarouk, K.O.; Stock, C.M.; Taylor, S.; Walsh, M.; Muddathir, A.K.; Verduzco, D.; Bashir, A.H.H.; Mohammed, O.Y.; Elhassan, G.O.; Harguindey, S.; et al. Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell Int. 2015, 15, 1–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Assaraf, Y.G.; Brozovic, A.; Gonçalves, A.C.; Jurkovicova, D.; Linē, A.; Machuqueiro, M.; Saponara, S.; Sarmento-Ribeiro, A.B.; Xavier, C.P.R.; Vasconcelos, M.H. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist. Updates 2019, 46, 1–30. [Google Scholar] [CrossRef] [PubMed]
- Scripture, C.D.; Figg, W.D. Drug interactions in cancer therapy. Nat. Rev. Cancer 2006, 6, 546–558. [Google Scholar] [CrossRef] [PubMed]
- El-Awady, R.; Saleh, E.; Hashim, A.; Soliman, N.; Dallah, A.; Elrasheed, A.; Elakraa, G. The role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy. Front. Pharmacol. 2017, 7, 535. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meschini, S.; Calcabrini, A.; Monti, E.; Del Bufalo, D.; Stringaro, A.; Dolfini, E.; Arancia, G. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. Int. J. Cancer 2000, 87, 615–628. [Google Scholar] [CrossRef]
- Colone, M.; Calcabrini, A.; Toccacieli, L.; Bozzuto, G.; Stringaro, A.; Gentile, M.; Cianfriglia, M.; Ciervo, A.; Caraglia, M.; Budillon, A.; et al. The multidrug transporter P-glycoprotein: A mediator of melanoma invasion? J. Investig. Dermatol. 2008, 128, 957–971. [Google Scholar] [CrossRef] [Green Version]
- Nanayakkara, A.K.; Follit, C.A.; Chen, G.; Williams, N.S.; Vogel, P.D.; Wise, J.G. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Sci. Rep. 2018, 8, 967. [Google Scholar] [CrossRef] [Green Version]
- Kathawala, R.J.; Gupta, P.; Ashby, C.R., Jr.; Chen, Z.-S. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist. Updates 2015, 18, 1–17. [Google Scholar] [CrossRef]
- Robey, R.W.; Pluchino, K.M.; Hall, M.D.; Fojo, A.T.; Bates, S.E.; Gottesman, M.M. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 2018, 18, 452–464. [Google Scholar] [CrossRef] [PubMed]
- Jaramillo, A.C.; Al Saig, F.; Cloos, J.; Jansen, G.; Peters, G.J. How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? Cancer Drug Resist. 2018, 1, 6–29. [Google Scholar] [CrossRef] [Green Version]
- Al-Akra, L.; Bae, D.-H.; Leck, L.Y.W.; Richardson, D.R.; Jansson, P.J. The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance. Biochim. Biophys. Acta (BBA) 2019, 1863, 1390–1397. [Google Scholar] [CrossRef] [PubMed]
- Marotta, L.L.; Polyak, K. Cancer stem cells: A model in the making. Curr. Opin. Genet. Dev. 2009, 19, 44–50. [Google Scholar] [CrossRef] [PubMed]
- De Angelis, M.L.; Francescangeli, F.; La Torre, F.; Zeuner, A. Stem cell plasticity and dormancy in the development of cancer therapy resistance. Front. Pharmacol. 2019, 9, 626. [Google Scholar] [CrossRef] [Green Version]
- Ramos, E.K.; Hoffmann, A.D.; Gerson, S.L.; Liu, H. New opportunities and challenges to defeat cancer stem cells. Trends Cancer 2017, 3, 780–796. [Google Scholar] [CrossRef]
- Santamaría, P.G.; Moreno-Bueno, G.; Cano, A. Contribution of epithelial plasticity to therapy resistance. J. Clin. Med. 2019, 8, 676. [Google Scholar] [CrossRef] [Green Version]
- Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 2016, 79, 629–661. [Google Scholar] [CrossRef] [Green Version]
- Watkins, R.; Wu, L.; Zhang, C.; Davis, R.M.; Xu, B. Natural products-based nanomedicine: Recent advances and issues. Int. J. Nanomed. 2015, 10, 6055–6074. [Google Scholar] [CrossRef] [Green Version]
- Patra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.R.; Rodriguez-Torres, M.D.P.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, G.; Swamy, M.K.; Sharma, S.; et al. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnol. 2018, 16, 71. [Google Scholar] [CrossRef] [Green Version]
- Markman, J.L.; Rekechenetskiy, A.; Holler, E.; Ljubimova, J.Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 2013, 65, 1866–1879. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pelaz, B.; Alexiou, C.; Alvarez-Puebla, R.A.; Alves, F.; Andrews, A.M.; Ashraf, S.; Balogh, L.P.; Ballerini, L.; Bestetti, A.; Brendel, C.; et al. Diverse application of nanomedicine. ACS Nano 2017, 11, 2313–2381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tran, S.; De Giovanni, P.-J.; Piel, B.; Rai, P. Cancer nanomedicine: A review of recent success in drug delivery. Clin. Transl. Med. 2017, 6, 44. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett. 2013, 8, 102. [Google Scholar] [CrossRef] [Green Version]
- Bombelli, C.; Stringaro, A.; Borocci, S.; Bozzuto, G.; Colone, M.; Giansanti, L.; Sgambato, R.; Toccacieli, L.; Mancini, G.; Molinari, A. Efficiency of liposomes in the delivery of a photosensitizer controlled by the stereochemistry of a gemini surfactant component. Mol. Pharm. 2010, 7, 130–137. [Google Scholar] [CrossRef]
- Muthu, M.S.; Leong, D.T.; Mei, L.; Feng, S.S. Nanotheranostics—application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014, 4, 660–677. [Google Scholar] [CrossRef]
- Xing, H.; Hwang, K.; Lu, Y. Recent developments of liposomes as nanocarriers for theranostic applications. Theranostics 2016, 6, 1336–1352. [Google Scholar] [CrossRef]
- Perche, F.; Torchilin, V.P. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J. Drug Deliv. 2013, 2013, 705265. [Google Scholar] [CrossRef] [Green Version]
- Yang, T.; Choi, M.K.; Cui, F.D.; Lee, S.J.; Chung, S.J.; Shim, C.K.; Kim, D.D. Antitumor effect of paclitaxel-loaded pegylated immunoliposomes against human breast cancer cells. Pharm. Res. 2007, 24, 2402–2411. [Google Scholar] [CrossRef]
- Torchilin, V.P. Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents. Ther. Deliv. 2010, 1, 257–272. [Google Scholar] [CrossRef]
- Allen, T.M.; Cullis, P.R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65, 36–48. [Google Scholar] [CrossRef] [PubMed]
- Needham, D.; Anyarambhatla, G.; Kong, G.; Dewhirst, M.W. A new temperature- sensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model. Cancer Res. 2000, 60, 1197–1201. [Google Scholar] [PubMed]
- Szwed, M.; Torgersen, M.L.; Kumari, R.V.; Yadava, S.K.; Pust, S.; Iversen, T.G.; Skotland, T.; Giri, J.; Sandvig, K. Biological response and cytotoxicity induced by lipid nanocapsules. J. Nanobiotechnol. 2020, 18, 5. [Google Scholar] [CrossRef] [PubMed]
- Aheget, H.; Tristán-Manzano, M.; Mazini, L.; Cortijo-Gutierrez, M.; Galindo-Moreno, P.; Herrera, C.; Martin, F.; Marchal, J.A.; Benabdellah, K. Exosome: A new player in translational nanomedicine. J. Clin. Med. 2020, 9, 2380. [Google Scholar] [CrossRef] [PubMed]
- Van Giau, V.; An, S.S.A. Emergence of exosomal miRNA as a diagnostic biomarker for Alzheimer’s disease. J. Neurol. Sci. 2016, 360, 141–152. [Google Scholar] [CrossRef] [PubMed]
- Simons, M.; Raposo, G. Exosomes-vesicular carriers for intracellular communication. Curr. Opin. Cell Biol. 2009, 21, 575–581. [Google Scholar] [CrossRef] [PubMed]
- Nieuwland, R.; Sturk, A. Why do cells release vesicles? Thromb. Res. 2010, 125, S49–S51. [Google Scholar] [CrossRef]
- Andreola, G.; Rivoltini, L.; Castelli, C.; Huber, V.; Perego, P.; Deho, P.; Squarcina, P.; Accornero, P.; Lozupone, F.; Lugini, L.; et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 2002, 195, 1303–1316. [Google Scholar] [CrossRef]
- Burgio, S.; Noori, L.; Marino Gammazza, A.; Campanella, C.; Logozzi, M.; Fais, S.; Bucchieri, F.; Cappello, F.; Caruso Bavisotto, C. Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma. Int. J. Mol. Sci. 2020, 21, 5432. [Google Scholar] [CrossRef]
- Huber, V.; Fais, S.; Iero, M.; Lugini, L.; Canese, P.; Squarcina, P.; Zaccheddu, A.; Colone, M.; Arancia, G.; Gentile, M.; et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: Role in immune escape. Gastroenterology 2005, 128, 1796–1804. [Google Scholar] [CrossRef]
- Burnouf, T.; Agrahari, V.; Agrahari, V. Extracellular vesicles as nanomedicine: Hopes and hurdles in clinical translation. Int. J. Nanomed. 2019, 14, 8847–8859. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, Q.; Li, M.; Wang, X.; Li, Q.; Wang, T.; Zhu, Q.; Zhou, X.; Wang, X.; Gao, X.; Li, X. Immune-related microRNAs are abundant in breast milk exosomes. Int. J. Biol. Sci. 2012, 8, 118–123. [Google Scholar] [CrossRef] [PubMed]
- Bard, M.P.; Hegmans, J.P.; Hemmes, A.; Luider, T.M.; Willemsen, R.; Severijnen, L.-A.A.; van Meerbeeck, J.P.; Burgers, S.A.; Hoogsteden, H.C.; Lambrecht, B.N. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am. J. Respir. Cell Mol. Biol. 2004, 31, 114–121. [Google Scholar] [CrossRef] [PubMed]
- EL Andaloussi, S.; Mäger, I.; O Breakefield, X.; Wood, M.J.A. Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 2013, 12, 347–357. [Google Scholar] [CrossRef] [PubMed]
- Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M.J.A. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29, 341–345. [Google Scholar] [CrossRef]
- Toffoli, G.; Hadla, M.; Corona, G.; Caligiuri, I.; Palazzolo, S.; Semeraro, S.; Gamini, A.; Canzonieri, V.; Rizzolio, F. Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. Nanomedicine (Lond) 2015, 10, 2963–2971. [Google Scholar] [CrossRef] [PubMed]
- Tian, Y.; Li, S.; Song, J.; Ji, T.; Zhu, M.; Anderson, G.J.; Wei, J.; Nie, G. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 3, 2383–2390. [Google Scholar] [CrossRef]
- Saari, H.; Lázaro-Ibáñez, E.; Viitala, T.; Vuorimaa-Laukkanen, E.; Siljander, P.; Yliperttula, M. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J. Control Release 2015, 220 (Pt B), 727–737. [Google Scholar] [CrossRef] [Green Version]
- Zhuang, X.; Xiang, X.; Grizzle, W.; Sun, D.; Zhang, S.; Axtell, R.C.; Ju, S.; Mu, J.; Zhang, L.; Steinman, L.; et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 2011, 19, 1769–1779. [Google Scholar] [CrossRef]
- Arndt, M.; Nairz, O.; Voss-Andreae, J.; Keller, C.; van der Zouw, G.; Zeilinger, A. Wave-particle duality of C60. Nature 1999, 401, 680–682. [Google Scholar] [CrossRef]
- Rosa, H.; Chan, M.; Carmen, K.; Fung, M.; Wen, J.L. Rapid assembly of carbon nanotubes for nanosensing by dielectrophoretic force. Nanotechnology 2004, 15, 672–677. [Google Scholar] [CrossRef]
- Fabbro, C.; Ali-Boucetta, H.; Da Ros, T.; Kostarelos, K.; Bianco, A.; Prato, M. Targeting carbon nanotubes against cancer. Chem. Commun. 2012, 48, 3911–3926. [Google Scholar] [CrossRef] [PubMed]
- Mattheolabakis, G.; Rigas, B.; Constantinides, P.P. Nanodelivery strategies in cancer chemotherapy: Biological rationale and pharmaceutical perspectives. Nanomedicine 2012, 7, 1577–1590. [Google Scholar] [CrossRef]
- Ponti, J.; Broggi, F.; Mariani, V.; De Marzi, L.; Colognato, R.; Marmorato, P.; Gioria, S.; Gilliland, D.; Garcìa, C.P.; Meschini, S.; et al. Morphological transformation induced by multiwall carbon nanotubes on Balb/3T3 cell model as in vitro end point of carcinogenic potential. Nanotoxicology 2012, 7, 221–233. [Google Scholar] [CrossRef]
- Zanni, E.; De Bellis, G.; Bracciale, M.; Broggi, A.; Santarelli, M.L.; Sarto, M.S.; Palleschi, C.; Uccelletti, D. Graphite nanoplatelets and Caenorhabditis elegans: Insights from an in vivo model. Nano Lett. 2012, 12, 2740–2744. [Google Scholar] [CrossRef] [PubMed]
- McCallion, C.; Burthem, J.; Rees-Unwin, K.; Golovanov, A.; Pluen, A. Graphene in therapeutics delivery: Problems, solutions and future opportunities. Eur. J. Pharm. Biopharm. 2016, 104, 235–250. [Google Scholar] [CrossRef]
- Dreyer, D.R.; Park, S.; Bielawski, C.W.; Ruoff, R.S. The chemistry of graphene oxide. Chem. Soc. Rev. 2010, 39, 228–240. [Google Scholar] [CrossRef]
- Fu, C.L.; Yang, X.N. Molecular simulation of interfacial mechanics for solvent exfoliation of graphene from graphite. Carbon 2013, 55, 350–360. [Google Scholar] [CrossRef]
- Patel, S.C.; Lee, S.; Lalwani, G.; Suhrland, C.; Chowdhury, S.M.; Sitharaman, B. Graphene-based platforms for cancer therapeutics. Ther. Deliv. 2016, 7, 101–116. [Google Scholar] [CrossRef] [Green Version]
- Yang, X.; Zhang, X.; Liu, Z.; Ma, Y.; Huang, Y.; Chen, Y. High efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide. J. Phys. Chem. C 2008, 112, 17554–17558. [Google Scholar] [CrossRef]
- Jokar, S.; Pourjavadi, A.; Adeli, M. Albumin-graphene oxideconjugates; carriers for anticancer drugs. RSC Adv. 2014, 4, 33001–33006. [Google Scholar] [CrossRef]
- Xu, Z.; Zhu, S.; Wang, M.; Li, Y.; Shi, P.; Huang, X. Delivery of paclitaxel using PEGylated graphene oxide as a nanocarrier. App. Mater. Interfaces 2015, 7, 1355–1363. [Google Scholar] [CrossRef] [PubMed]
- Kopeckova, K.; Eckschlager, T.; Sirc, J.; Hobzova, R.; Plch, J.; Hrabeta, J.; Michalek, J. Nanodrugs used in cancer therapy. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2019, 163, 122–131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cavalieri, F.; Colone, M.; Stringaro, A.; Tortora, M.; Calcabrini, A.; Zhou, M.; Ashokkumar, M. Influence of the morphology of lysozyme-shelled microparticles on the cellular association, uptake, and degradation in human adenocarcinoma cells. Part. Part. Syst. Charact. 2013, 30, 695–705. [Google Scholar] [CrossRef] [Green Version]
- Janib, S.M.; Moses, A.S.; MacKay, J.A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 2010, 62, 1052–1063. [Google Scholar] [CrossRef] [Green Version]
- Grossman, J.H.; McNeil, S.E. Nanotechnology in cancer medicine. Phys. Today 2012, 65, 38–42. [Google Scholar] [CrossRef] [Green Version]
- Gundogdu, N.; Cetin, M. Chitosan-poly (lactide-coglycolide) (CS-PLGA) nanoparticles containing metformin HCl: Preparation and in vitro evaluation. Pak. J. Pharm. Sci. 2014, 27, 1923–1929. [Google Scholar]
- Tajmir-Riahi, H.A.; Nafisi, S.; Sanyakamdhorn, S.; Agudelo, D.; Chanphai, P. Applications of chitosan nanoparticles in drug delivery. Methods Mol. Biol. 2014, 1141, 165–184. [Google Scholar] [CrossRef]
- Malhotra, M.; Tomaro-Duchesneau, C.; Saha, S.; Prakash, S. Intranasal delivery of chitosan-siRNA nanoparticle formulation to the brain. Methods Mol. Biol. 2014, 1141, 233–247. [Google Scholar] [CrossRef]
- Raja, M.A.G.; Katas, H.; Wen, T.J. Stability, intracellular delivery, and release of siRNA from chitosan nanoparticles using different cross-linkers. PLoS ONE 2015, 10, e0128963. [Google Scholar] [CrossRef]
- Kaldybekov, D.B.; Filippov, S.K.; Radulescu, A.; Khutoryanskiy, V.V. Maleimide-functionalised PLGA-PEG nanoparticles as mucoadhesive carriers for intravesical drug delivery. Eur. J. Pharm. Biopharm. 2019, 143, 24–34. [Google Scholar] [CrossRef] [PubMed]
- Colone, M.; Kaliappan, S.; Calcabrini, A.; Tortora, M.; Cavalieri, F.; Stringaro, A. Redox-active microcapsules as drug delivery system in breast cancer cells and spheroids. J. Mol. Genet. Med. 2016, 10, 1–6. [Google Scholar] [CrossRef]
- Brzeziński, M.; Wedepohl, S.; Kost, B.; Calderón, M. Nanoparticles from supramolecular polylactides overcome drug resistance of cancer cells. Eur. Polymer J. 2018, 109, 117–123. [Google Scholar] [CrossRef]
- Miele, E.; Spinelli, G.P.; Miele, E.; Tomao, F.; Tomao, S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int. J. Nanomed. 2009, 4, 99–105. [Google Scholar] [CrossRef] [Green Version]
- Hawkins, M.J.; Soon-Shiong, P.; Desai, N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug. Deliv. Rev. 2008, 60, 876–885. [Google Scholar] [CrossRef] [PubMed]
- Zheng, Y.R.; Suntharalingam, K.; Johnstone, T.C.; Lippard, S.J. Encapsulation of Pt (IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J. Am. Chem. Soc. 2014, 136, 8790–8798. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cirstea, D.; Hideshima, T.; Rodig, S.; Santo, L.; Pozzi, S.; Vallet, S.; Ikeda, H.; Perrone, G.; Gorgun, G.; Patel, K.; et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol. Cancer. Ther. 2010, 9, 963–975. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fu, Q.; Sun, J.; Zhang, W.; Sui, X.; Yan, Z.; He, Z. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent. Pat. Anticancer Drug. Discov. 2009, 4, 262–272. [Google Scholar] [CrossRef] [PubMed]
- Von Hoff, D.D.; Mita, M.M.; Ramanathan, R.K.; Weiss, G.J.; Mita, A.C.; LoRusso, P.M.; Burris, H.A., III; Hart, L.L.; Low, S.C.; Parsons, D.M.; et al. Phase I study of PSMA-Targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin. Cancer Res. 2016, 22, 3157–3163. [Google Scholar] [CrossRef] [Green Version]
- Jung, H.S.; Han, J.; Lee, J.H.; Lee, J.H.; Choi, J.M.; Kweon, H.S.; Han, J.H.; Kim, J.H.; Byun, K.M.; Jung, J.H.; et al. Enhanced NIR radiation-triggered hyperthermia by mitochondrial targeting. J. Am. Chem. Soc. 2015, 137, 3017–3023. [Google Scholar] [CrossRef]
- Chen, P.C.; Mwakwari, S.C.; Oyelere, A.K. Gold nanoparticles: From nanomedicine to nanosensing. Nanotechnol. Sci. Appl. 2008, 1, 45–65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, Y.Y.; Jin, K.-T.; Wan, S.B.; Wang, H.J.; Tong, X.M.; Huang, D.; Mou, X.Z. Molecular Imaging of Cancer with Nanoparticle-Based Theranostic Probes. Contrast Media Mol. Imaging 2017, 19, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duncan, R.; Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011, 8, 2101–2141. [Google Scholar] [CrossRef] [PubMed]
- Huang, C.; Barua, S.; Sharma, G.; Dey, S.K.; Rege, K. Inorganic nanoparticles for cancer imaging and therapy. J. Control Release 2011, 155, 344–357. [Google Scholar] [CrossRef]
- Libutti, S.K.; Paciotti, G.F.; Byrnes, A.A.; Alexander, H.R.J.; Gannon, W.E.; Walker, M.; Seidel, G.D.; Yuldasheva, N.; Tamarkin, L. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res. 2010, 16, 6139–6149. [Google Scholar] [CrossRef] [Green Version]
- Li, Z.; Tan, S.; Li, S.; Shen, Q.; Wang, K. Cancer drug delivery in the nano era: An overview and perspectives (Review). Oncol. Rep. 2017, 38, 611–624. [Google Scholar] [CrossRef] [Green Version]
- Benezra, M.; Penate-Medina, O.; Zanzonico, P.; Schaer, D.; Ow, H.; Burns, A.; DeStanchina, E.; Longo, V.; Herz, E.; Iyer, S.; et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Investig. 2011, 121, 2768–2780. [Google Scholar] [CrossRef] [Green Version]
- Sanchez, C.; Belleville, P.; Popall, M.; Nicole, L. Applications of advanced hybrid organic-inorganic nanomaterials: From labora-tory to market. Chem. Soc. Rev. 2011, 40, 696–753. [Google Scholar] [CrossRef]
- Greish, K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol. Biol. 2010, 624, 25–37. [Google Scholar] [CrossRef]
- Li, Y.; Wang, J.; Wientjes, M.G.; Au, J.L. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv. Drug Deliv. Rev. 2012, 64, 29–39. [Google Scholar] [CrossRef] [Green Version]
- Sharma, A.; Jain, N.; Sareen, R. Nanocarriers for diagnosis and targeting of breast cancer. Biomed. Res. Int. 2013, 2013, 960821. [Google Scholar] [CrossRef] [PubMed]
- Gref, R.; Minamitake, Y.; Peracchia, M.T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263, 1600–1603. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, M.; Nie, G.; Meng, H.; Xia, T.; Nel, A.; Zhao, Y. Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Acc. Chem. Res. 2013, 46, 622–631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nagaraju, G.P.; Srivani, G.; Dariya, B.; Chalikonda, G.; Farran, B.; Behera, S.K.; Alam, A.; Kamal, M.A. Nanoparticles guided drug delivery and imaging in gastric cancer. Semin Cancer Biol. 2020, 16, 1–35. [Google Scholar] [CrossRef]
- Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug. Deliv. Rev. 2004, 56, 1649–1659. [Google Scholar] [CrossRef]
- Ferrari, M. Frontiers in cancer nanomedicine: Directing mass transport through biological barriers. Trends Biotechnol. 2010, 28, 181–188. [Google Scholar] [CrossRef] [Green Version]
- Tasciotti, E.; Liu, X.; Bhavane, R.; Plant, K.; Leonard, A.D.; Price, B.K.; Cheng, M.M.; Decuzzi, P.; Tour, J.M.; Robertson, F.; et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 2008, 3, 151–157. [Google Scholar] [CrossRef]
- Tanaka, T.; Decuzzi, P.; Cristofanilli, M.; Sakamoto, J.H.; Tasciotti, E.; Robertson, F.M.; Ferrari, M. Nanotechnology for breast cancer therapy. Biomed. Microdevices 2009, 11, 49–63. [Google Scholar] [CrossRef]
- Etheridge, M.L.; Campbell, S.A.; Erdman, A.G.; Haynes, C.L.; Wolf, S.M.; McCullough, J. The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomedicine 2013, 9, 1–14. [Google Scholar] [CrossRef] [Green Version]
- Hay, M.; Thomas, D.W.; Craighead, J.L.; Economides, C.; Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 2014, 32, 40–51. [Google Scholar] [CrossRef]
- Detsi, A.; Kavetsou, E.; Kostopoulou, I.; Pitterou, I.; Nefeli Pontillo, A.R.; Tzani, A.; Christodoulou, P.; Siliachli, A.; Zoumpoulakis, P. Nanosystems for the encapsulation of natural products: The case of chitosan biopolymer as a matrix. Pharmaceutics 2020, 12, 669. [Google Scholar] [CrossRef] [PubMed]
- Katz, L.; Baltz, R.H. Natural product discovery: Past, present, and future. J. Ind. Microbiol. Biotechnol. 2016, 43, 155–176. [Google Scholar] [CrossRef] [PubMed]
- Das, S.; Singh, V.K.; Dwivedy, A.K.; Chaudhari, A.K.; Upadhyay, N.; Singh, P.; Sharma, S.; Dubey, N.K. Encapsulation in chitosan-based nanomatrix as an efficient green technology to boost the antimicrobial, antioxidant and in situ effcacy of Coriandrum sativum essential oil. Int. J. Biol. Macromol. 2019, 133, 294–305. [Google Scholar] [CrossRef]
- Shetta, A.; Kegere, J.; Mamdouh, W. Comparative study of encapsulated peppermint and green tea essential oils in chitosan nanoparticles: Encapsulation, thermal stability, in-vitro release, antioxidant and antibacterial activities. Int. J. Biol. Macromol. 2019, 126, 731–742. [Google Scholar] [CrossRef] [PubMed]
- Feyzioglu, G.C.; Tornuk, F. Development of chitosan nanoparticles loadedwith summer savory (Saturejahortensis L.) essential oil for antimicrobial and antioxidant delivery applications. LWT 2016, 70, 104–110. [Google Scholar] [CrossRef]
- Ntohogian, S.; Gavriliadou, V.; Christodoulou, E.; Nanaki, S.; Lykidou, S.; Naidis, P.; Mischopoulou, L.; Barmpalexis, P.; Nikolaidis, N.; Bikiaris, D.N. Chitosan nanoparticles with encapsulated natural and uf-purified annatto and saffron for the preparation of uv protective cosmetic emulsions. Molecules 2018, 23, 2107. [Google Scholar] [CrossRef] [Green Version]
- Hussein, A.M.; Kamil, M.M.; Lotfy, S.N.; Mahmoud, K.F.; Mehaya, F.M.; Mohammad, A.A. Influence of nano-encapsulation on chemical composition, antioxidant activity and thermal stability of rosemary essential oil. Am. J. Food Technol. 2017, 12, 170–177. [Google Scholar] [CrossRef]
- Diasn, D.A.; Urban, S.; Roessner, U. A historical overview of natural products in drug discovery. Metabolites 2012, 16, 303–336. [Google Scholar] [CrossRef] [Green Version]
- Cragg, G.M.; Newman, D.J. Natural products: A continuing source of novel drug leads. Biochim. Biophys. Acta 2013, 1830, 3670–3695. [Google Scholar] [CrossRef] [Green Version]
- Aqil, F.; Munagala, R.; Jeyabalan, J.; Vadhanam, M.V. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 2013, 28, 133–141. [Google Scholar] [CrossRef] [Green Version]
- Demain, A.L.; Vaishnav, P. Natural products for cancer chemotherapy. Microb. Biotechnol. 2011, 4, 687–699. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harvey, A.L.; Edrada-Ebel, R.; Quinn, R.J. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug. Discov. 2015, 14, 111–129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Waksman, S.A.; Woodruff, H.B. Actinomyces antibioticus, a new soil organism antagonistic to pathogenic and non-pathogenic bacteria. J. Bacteriol. 1941, 42, 231–249. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weaver, B.A. How Taxol/paclitaxel kills cancer cells. Mol. Biol. Cell. 2014, 25, 2677–2681. [Google Scholar] [CrossRef]
- Amaral, R.G.; Albuquerque dos Santos, S.; Nalone Andrade, L.; Severino, P.; Andrade Carvalho, A. Natural Products as Treatment against Cancer: A Historical and Current vision. Clin. Oncol. 2019, 4, 1562. [Google Scholar]
- Atanasov, A.G.; Waltenberger, B.; Pferschy-Wenzig, E.M.C.; Linder, T.; Wawrosch, C.; Uhrin, P.; Temml, V.; Wang, L.; Schwaiger, S.; Heiss, E.H.; et al. Discovery and resupply of pharmacologically active plant—derived natural products: A review. Biotechnol. Adv. 2015, 33, 1582–1614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bernardo, A.; Palumbo, R.; Pedersini, R.; Rota Caremoli, E.; Gambaro, A.R.; Ferzi, A.; Riva, F.; Grasso, D.; Danova, M.; Tarenzi, E.; et al. Nab-Paclitaxel in advanced HER2-negative breast cancer patients: Efficacy and safety beyond clinical trials. Clin. Breast Cancer 2017, 17, 433–440. [Google Scholar] [CrossRef]
- Bilia, A.R.; Piazzini, V.; Guccione, C.; Risaliti, L.; Asprea, M.; Capecchi, G.; Bergonzi, M.C. Improving on nature: The role of nanomedicine in the development of clinical natural drugs. Planta Med. 2017, 83, 366–381. [Google Scholar] [CrossRef] [Green Version]
- Yetisgin, A.A.; Cetinel, S.; Zuvin, M.; Kosar, A.; Kutlu, O. Therapeutic nanoparticles and their targeted delivery applications. Molecules 2020, 25, 2193. [Google Scholar] [CrossRef]
- Montané, X.; Bajek, A.; Roszkowski, K.; Montornés, J.M.; Giamberini, M.; Roszkowski, S.; Kowalczyk, O.; Garcia-Valls, R.; Tylkowski, B. Encapsulation for Cancer Therapy. Molecules 2020, 25, 1605. [Google Scholar] [CrossRef] [Green Version]
- Bozzuto, G.; Molinari, A. Liposomes as nanomedical devices. Int. J. Nanomed. 2015, 10, 975–999. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, L.; Zhang, B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci. Rep. 2017, 7, 44735. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dai, L.; Yu, Y.; Luo, Z.; Li, M.; Chen, W.; Shen, X.; Chen, F.; Sun, Q.; Zhang, Q.; Gu, H.; et al. Photosensitizer enhanced disassembly of amphiphilic micelle for ROS-response targeted tumor therapy in vivo. Biomaterials 2016, 104, 1–17. [Google Scholar] [CrossRef] [PubMed]
- Kharlamov, A.N.; Feinstein, J.A.; Cramer, J.A.; Boothroyd, J.A.; Shishkina, E.V.; Shur, V. Plasmonic photothermal therapy of atherosclerosis with nanoparticles: Long-term outcomes and safety in NANOM-FIM trial. Future Cardiol. 2017, 13, 345–363. [Google Scholar] [CrossRef] [PubMed]
- Madamsetty, V.S.; Pal, K.; Keshavan, S.; Caulfield, T.R.; Dutta, S.K.; Wang, E.; Fadeel, B.; Mukhopadhyay, D. Development of multi-drug loaded PEGylated nanodiamonds to inhibit tumor growth and metastasis in genetically engineered mouse models of pancreatic cancer. Nanoscale 2019, 11, 22006–22018. [Google Scholar] [CrossRef]
- Murakami, M.; Cabral, H.; Matsumoto, Y.; Wu, S.; Kano, M.R.; Yamori, T.; Nishiyama, N.; Kataoka, K. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci. Transl. Med. 2011, 3, 64ra2. [Google Scholar] [CrossRef]
- Yao, Y.; Zhou, Y.; Liu, L.; Xu, Y.; Chen, Q.; Wang, Y.; Wu, S.; Deng, Y.; Zhang, J.; Shao, A. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front. Mol. Biosci. 2020, 20, 193. [Google Scholar] [CrossRef]
- Cheng, H.; Wu, Z.; Wu, C.; Wang, X.; Liow, S.S.; Li, Z.; Wu, Y.-L. Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHBPDMAEMA cationic polyester in liver cancer cells. Mater. Sci. Eng. C Mater. Biol. Appl. 2018, 83, 210–217. [Google Scholar] [CrossRef]
- Ko, J.H.; Sethi, G.; Um, J.Y.; Shanmugam, M.K.; Arfuso, F.; Kumar, A.P.; Bishayee, A.; Ahn, K.S. The role of resveratrol in cancer therapy. Int. J. Mol. Sci. 2017, 18, 2589. [Google Scholar] [CrossRef] [Green Version]
- Zhao, Y.; Huan, M.L.; Liu, M.; Cheng, Y.; Sun, Y.; Cui, H.; Liu, D.; Mei, Q.; Zhou, S. Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance. Sci. Rep. 2016, 6, 35267. [Google Scholar] [CrossRef]
- Singh, S.K.; Lillard, J.W., Jr.; Singh, R. Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. Cancer Lett. 2018, 427, 49–62. [Google Scholar] [CrossRef] [PubMed]
- Condello, M.; Cosentino, D.; Corinti, S.; Di Felice, G.; Multari, G.; Gallo, F.R.; Arancia, G.; Meschini, S. Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts. J. Nat. Prod. 2014, 77, 855–862. [Google Scholar] [CrossRef] [PubMed]
- Giansanti, L.; Condello, M.; Altieri, B.; Galantini, L.; Meschini, S.; Mancini, G. Influence of lipid composition on the ability of liposome loaded voacamine to improve the reversion of doxorubicin resistant osteosarcoma cells. Chem. Phys. Lipids 2019, 223, 104781. [Google Scholar] [CrossRef] [PubMed]
- Gupta, U.; Sharma, S.; Khan, I.; Gothwal, A.; Sharma, A.K.; Singh, Y.; Chourasia, M.K.; Kumar, V. Enhanced apoptotic and anticancer potential of paclitaxel loaded biodegradable nanoparticles based on chitosan. Int. J. Biol. Macromol. 2017, 98, 810–819. [Google Scholar] [CrossRef] [PubMed]
- Maeng, J.H.; Lee, D.H.; Jung, K.H.; Bae, Y.H.; Park, I.S.; Jeong, S.; Jeon, Y.S.; Shim, C.K.; Kim, W.; Kim, J.; et al. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 2010, 31, 4995–5006. [Google Scholar] [CrossRef] [PubMed]
- Pulido-Moran, M.; Moreno-Fernandez, J.; Ramirez-Tortosa, C.; Ramirez-Tortosa, M.C. Curcumin and Health. Molecules 2016, 21, 264. [Google Scholar] [CrossRef] [PubMed]
- Feng, T.; Wei, Y.; Lee, R.J.; Zhao, L. Liposomal curcumin and its application in cancer. Int. J. Nanomed. 2017, 12, 6027–6044. [Google Scholar] [CrossRef] [Green Version]
- Nasery, M.M.; Banafshe, A.; Poormoghadam, D.; Zarrabi, A.; Keyhanvar, P. Curcumin delivery mediated by bio-based nanoparticles: A review. Molecules 2020, 25, 689. [Google Scholar] [CrossRef] [Green Version]
- Cheng, C.; Peng, S.; Li, Z.; Zou, L.; Liu, W.; Liu, C. Improved bioavailability of curcumin in liposomes prepared using a pH-driven, organic solvent- free, easily scalable process. RSC Adv. 2017, 7, 25978–25986. [Google Scholar] [CrossRef] [Green Version]
- Greil, R.; Greil-Ressler, S.; Weiss, L.; Schönlieb, C.; Magnes, T.; Radl, B.; Bolger, G.T.; Vcelar, B.; Sordillo, P.P. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (LipocurcTM) in patients with locally advanced or metastatic cancer. Cancer Chemother. Pharmacol. 2018, 82, 695–706. [Google Scholar] [CrossRef] [Green Version]
- Storka, A.; Vcelar, B.; Klickovic, U.; Gouya, G.; Weisshaar, S.; Aschauer, S.; Bolger, G.; Helson, L.; Wolzt, M. Safety, tolerability and pharmacokinetics of liposomal curcumin (LipocurcTM) in healthy humans. Int. J. Clin. Pharmacol. Ther. 2015, 53, 54–65. [Google Scholar] [CrossRef] [PubMed]
- Madamsetty, V.S.; Sharma, A.; Toma, M.; Samaniego, S.; Gallud, A.; Wang, E.; Pal, K.; Mukhopadhyay, D.; Fadeel, B. Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer. Nanomed. Nanotechnol. Biol. Med. 2019, 18, 112–121. [Google Scholar] [CrossRef] [PubMed]
- Weathers, P.J.; Arsenault, P.R.; Covello, P.S.; McMickle, A.; Teoh, K.H.; Reed, D.W. Artemisinin production in Artemisia annua: Studies in planta and results of a novel delivery method for treating malaria and other neglected diseases. Phytochem. Rev. 2011, 10, 173–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kiani, B.H.; Kayani, W.K.; Khayam, A.U.; Dilshad, E.; Ismail, H.; Mirza, B. Artemisinin and its derivatives: A promising cancer therapy. Mol. Biol. Rep. 2020, 47, 6321–6336. [Google Scholar] [CrossRef]
- Efferth, T.; Romero, M.R.; Bilia, A.R.; Osman, A.G.; ElSohly, M.; Wink, M.; Bauer, R.; Khan, I.; Bergonzi, M.C.; Marin, J.J.G. Expanding the therapeutic spectrum of artemisinin: Activity against infectious diseases beyond malaria and novel pharmaceutical developments. World J. Tradit. Chin. Med. 2016, 2, 1–23. [Google Scholar] [CrossRef]
- Leto, I.; Coronnello, M.; Righeschi, C.; Bergonzi, M.C.; Mini, E.; Bilia, A.R. Enhanced efficacy of artemisinin loaded in transferrin-conjugated liposomes versus stealth liposomes against HCT-8 colon cancer cells. Chem. Med. Chem. 2016, 11, 1745–1751. [Google Scholar] [CrossRef]
- Singh, S.K.; Banerjee, S.; Acosta, E.P.; Lillard, J.W.; Singh, R. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget 2017, 8, 17216–17228. [Google Scholar] [CrossRef] [Green Version]
- Shao, J.; Li, X.; Lu, X.; Jiang, C.; Hu, Y.; Li, Q.; You, Y.; Fu, Z. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf. B. Biointerfaces 2009, 72, 40–47. [Google Scholar] [CrossRef]
- Caddeo, C.; Teskac, K.; Sinico, C.; Kristl, J. Effect of resveratrol incorporated in liposomes on proliferation and UVB protection of cells. Int. J. Pharm. 2008, 363, 183–191. [Google Scholar] [CrossRef]
- Bilia, A.R.; Guccione, C.; Isacchi, B.; Righeschi, C.; Firenzuoli, F.; Bergonzi, M.C. Essential oils loaded in nanosystems: A developing strategy for a successful therapeutic approach. Evid.-Based Complement. Alternat. Med. 2014, 1–14. [Google Scholar] [CrossRef] [Green Version]
- Obeid, M.A.; Al Qaraghuli, M.M.; Alsaadi, M.; Alzahrani, A.R.; Niwasabutra, K.; Ferro, V.A. Delivering natural products and biotherapeutics to improve drug efficacy. Ther. Deliv. 2017, 8, 947–956. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shi, F.; Zhao, J.H.; Liu, Y.; Wang, Z.; Zhang, Y.T.; Feng, N.P. Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil. Int. J. Nanomed. 2012, 7, 2033–2043. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guimarães, A.G.; Oliveira, M.A.; Alves, R.d.S.; Menezes, P.P.; Serafini, M.R.; Araújo, A.A.; Bezerra, D.P.; Quintans-Júnior, L.J. Encapsulation of carvacrol, a monoterpene present in the essential oil of oregano, with β-cyclodextrin, improves the pharmacological response on cancer pain experimental protocols. Chem. Biol. Interact. 2015, 227, 69–76. [Google Scholar] [CrossRef]
- Srinivas, G.; Babykutty, S.; Sathiadevan, P.P.; Srinivas, P. Molecular mechanism of emodin action: Transition from laxative ingredient to an antitumor agent. Med. Res. Rev. 2007, 27, 591–608. [Google Scholar] [CrossRef]
- Chen, S.H.; Lin, K.Y.; Chang, C.C.; Fang, C.L.; Lin, C.P. Aloe-emodin-induced apoptosis in human gastric carcinoma cells. Food Chem. Toxicol. 2007, 45, 2296–2303. [Google Scholar] [CrossRef]
- Tabolacci, C.; Lentini, A.; Mattioli, P.; Provenzano, B.; Oliverio, S.; Carlomosti, F.; Beninati, S. Antitumor properties of aloe-emodin and induction of transglutaminase 2 activity in B16-F10 melanoma cells. Life Sci. 2010, 87, 316–324. [Google Scholar] [CrossRef]
- Pecere, T.; Gazzola, M.V.; Mucignat, C.; Parolin, C.; Dalla Vecchia, F.; Cavaggioni, A.; Basso, G.; Diaspro, A.; Salvato, B.; Carli, M.; et al. Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. Cancer Res. 2000, 60, 2800–2804. [Google Scholar]
- Chen, R.; Zhang, J.; Hu, Y.; Wang, S.; Chen, M.; Wang, Y. Potential antineoplastic effects of Aloe-emodin: A comprehensive review. Am. J. Chin. Med. 2014, 42, 275–288. [Google Scholar] [CrossRef]
- Suboj, P.; Babykutty, S.; Srinivas, P.; Gopala, S. Aloe emodin induces G2/M cell cycle arrest and apoptosis via activation of caspase-6 in human colon cancer cells. Pharmacology 2012, 89, 91–98. [Google Scholar] [CrossRef]
- Guo, J.M.; Xiao, B.X.; Liu, Q.; Zhang, S.; Liu, D.H.; Gong, Z.H. Anticancer effect of aloe-emodin on cervical cancer cells involves G2/M arrest and induction of differentiation. Acta Pharmacol. Sin. 2007, 28, 1991–1995. [Google Scholar] [CrossRef] [Green Version]
- Giuliani, C.; Altieri, B.; Bombelli, C.; Galantini, L.; Mancini, M.; Stringaro, A. Remote loading of Aloe Emodin in Gemini-based cationic liposomes. Langmuir 2015, 31, 76–82. [Google Scholar] [CrossRef] [PubMed]
- Li, K.-T.; Duan, Q.-Q.; Chen, Q.; He, J.-W.; Tian, S.; Lin, H.-D.; Gao, Q.; Bai, D.-Q. The effect of aloe emodin-encapsulated nanoliposome mediated r-caspase-3 gene transfection and photodynamic therapy on human gastric cancer cells. Cancer Med. 2016, 5, 361–369. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fujiwara, Y.; Mukai, H.; Saeki, T.; Ro, J.; Lin, Y.-C.; Nagai, S.E.; Lee, K.S.; Watanabe, J.; Ohtani, S.; Kim, S.B.; et al. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br. J. Cancer 2019, 120, 475–480. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- A Clinical Study to Measure the Effect of OP-101 after Being Administered Subcutaneous in Healthy Volunteers. Available online: https://ClinicalTrials.gov/show/NCT04321980:2018 (accessed on 1 July 2020).
- Bahrami, B.; Hojjat-Farsangi, M.; Mohammadi, H.; Anvari, E.; Ghalamfarsa, G.; Yousefi, M.; Jadidi-Niaragh, F. Nanoparticles and targeted drug delivery in cancer therapy. Immunol. Lett. 2017, 190, 64–83. [Google Scholar] [CrossRef] [PubMed]
- Farokhzad, O.C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 27, 16–20. [Google Scholar] [CrossRef]
- Kim, K.; Khang, D. Past, Present, and Future of Anticancer Nanomedicine. Int. J. Nanomed. 2020, 6, 5719–5743. [Google Scholar] [CrossRef]
- Rahman, H.S.; Othman, H.H.; Hammadi, N.I.; Yeap, S.K.; Amin, K.M.; Abdul Samad, N.; Alitheen, N.B. Novel drug delivery systems for loading of natural plant extracts and their biomedical applications. Int. J. Nanomed. 2020, 15, 2439–2483. [Google Scholar] [CrossRef] [Green Version]
- Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54, 987–992. [Google Scholar]
- Swenson, C.E.; Perkins, W.R.; Roberts, P.; Janoff., A.S. Liposome technology and the development of MyocetTM (liposomal doxorubicin citrate). Breast 2001, 10, 1–7. [Google Scholar] [CrossRef]
- Fassas, A.; Anagnostopoulos, A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk. Lymphoma 2005, 46, 795–802. [Google Scholar] [CrossRef]
- Lencioni, R.; Cioni, D. RFA plus lyso-thermosensitive liposomal doxorubicin: In search of the optimal approach to cure intermediate-size hepatocellular carcinoma. Hepat. Oncol. 2016, 3, 193–200. [Google Scholar] [CrossRef] [PubMed]
- Silverman, A.J.; Deitcher, S.R. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol. 2013, 71, 555–564. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kundranda, M.N.; Niu, J. Albumin-bound paclitaxel in solid tumors: Clinical development and future directions. Drug Des. Devel. Ther. 2015, 9, 3767–3777. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Nanomaterials | Passive Targeting | Active Targeting | Advantages | Disadvantages |
---|---|---|---|---|
Lipid based NPs | Accumulate through the EPR effect | Possibility to decorate with specific ligand | Biocompatible, biodegradable, reduced toxicity | High Clearance via RES |
Carbon based NPs | Promoting increased accumulation in tumor sites | Lower toxicity, increased efficacy | Biocompatible | Immunogenic, thrombotic |
Polymeric NPs | Prolonged circulation times | Higher drug concentration in tumor sites | Easy design, wide shape variabilities | Induction of inflammatory processes |
Metallic and Magnetic NPs | Combination of diagnosis and treatment | Involved in multimodal cancer treatment to enhance drug accumulation | No specific drug distribution | Possible high toxicity and low stability and biocompatibility |
Natural Product | NPs | Evaluation | Ref. |
---|---|---|---|
Paclitaxel (PTX) | Cationic nanoparticle complex | in vitro | [131] |
Resveratrol plus Doxorubicin | Poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles | in vitro | [133] |
Resveratrol plus Docetaxel | Planetary ball milled (PBM) nanoparticles | in vitro | [134] |
PTX | Chitosan-based nanoparticles | in vitro | [137] |
Curcumin | Liposomes | in vitro | [142] |
Artemisinin | PEGylated nanoliposomes | in vitro | [149] |
Resveratrol | mPEG poly (epsiloncaprolactone) nanoparticles | in vitro | [151] |
Resveratrol | Liposomes | in vitro | [152] |
Doxil® (Doxorubicin) | Iron oxide nanoparticles | in vivo | [138] |
Irinotecan plus Curcumin | PEGylated nanodiamonds | in vivo | [128] |
Frankincense and Myrrh oil (FMO) | Solid lipid nanoparticles | in vivo | [155] |
Carvacrol | Complex of β-cyclodextrin | in vivo | [156] |
PTX | Polymeric micelles NK105 | Clinical trial | [166] |
PTX plus mAb anti-HER2+ | Pegylated Immunoliposomes | Clinical trial | [32] |
Doxo plus mAb 2C5 | Liposomes | Clinical trial | [33] |
N-acetyl-cysteine | Dendrimer OP-101 | Clinical trial | [167] |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Colone, M.; Calcabrini, A.; Stringaro, A. Drug Delivery Systems of Natural Products in Oncology. Molecules 2020, 25, 4560. https://doi.org/10.3390/molecules25194560
Colone M, Calcabrini A, Stringaro A. Drug Delivery Systems of Natural Products in Oncology. Molecules. 2020; 25(19):4560. https://doi.org/10.3390/molecules25194560
Chicago/Turabian StyleColone, Marisa, Annarica Calcabrini, and Annarita Stringaro. 2020. "Drug Delivery Systems of Natural Products in Oncology" Molecules 25, no. 19: 4560. https://doi.org/10.3390/molecules25194560